Tag: NASH

Notizia

Business Consultant, DelveInsight's Drug Report, Notizia, Pharma Consultant

Lilly tests the efficacy of Tirzepatide-a novel dual GIP, GLP-1 agonist Eli Lilly is planning to test its diabetes drug Tirzepatide in a...

Read More

NASH Emerging Therapies

Articles, Business Consultant, DelveInsight's Drug Report, Pharma Consultant

Earlier in our article, we discussed how mostly off-label therapies so far dominate the NASH therapeutics market. So, let us dig deeper...

Read More

Notizia

Business Consultant, Notizia, Oncology based Indications, Pharma Consultant

FDA gives thumbs-up to Balversa The U.S. FDA has granted approval of Balversa (erdafitinib) to Belgium-based Janssen Pharmaceutica, for the...

Read More

Notizia

Business Consultant, Chimeric Antigen Receptor (CAR) T-cell Therapy, DelveInsight's Drug Report, Notizia, Pharma Consultant

Anylam, Regeneron to broaden the scope of R&D in Pharma Alnylam in collaboration with Regeneron is expanding its research on NASH....

Read More

Nonalcoholic Steatohepatitis (NASH): Highly Epidemic

Articles, Business Consultant, Pharma Consultant

Obesity and diabetes are a global epidemic contributing to an increasing prevalence of related systemic disorders, including non-alcoholic...

Read More
Close